Ret Proto-Oncogene antibody (AA 702-848)

Catalog No. ABIN6940507

Product Details anti-Ret Proto-Oncogene Antibody

Target: Ret Proto-Oncogene (RET)

Binding Specificity: AA 702-848

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Ret Proto-Oncogene antibody is un-conjugated

Application: Immunohistochemistry (IHC), Staining Methods (StM)

Purification: Purified by Protein A/G

Immunogen: Recombinant fragment (around aa 702-848) of human RET protein (exact sequence is proprietary)

Clone: RET-2795

Isotype: IgG1 kappa

Application Details

Application Notes:

Positive Control: Breast, Prostate or Colon Carcinoma.

Known Application: Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT)(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM Tris with 1 mM EDTA, pH 9.0, for 10-20 min followed by cooling at RT for 20 minutes)Optimal dilution for a specific application should be determined.

Restrictions: For Research Use only

Handling

Concentration: 200 μg/mL

Buffer: 10 mM PBS with 0.05 % BSA & 0.05 % azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-80 °C

Storage Comment: Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

Expiry Date: 24 months

Target Details for Ret Proto-Oncogene

Target: Ret Proto-Oncogene (RET)

Alternative Name: RET (RET Products)

Background: The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. RET expression is reported in several regions of the central nervous system, in the developing cranial nerve ganglia and a subset of cells within dorsal root ganglia, in motor neurons in the spinal cord and hindbrain, in neuro-retina and the growing tips of the renal collecting ducts in developing kidney.Alterations in RETgene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma, and a congenital developmental disorder known as Hirschsprung's disease.

Molecular Weight: 150kDa (precursor), 170kDa (Mature)

Gene ID: 5979

UniProt: P07949

Pathways: RTK Signaling, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation